Greenwich LifeSciences, Inc.
GLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $13 | $8 | $6 | $4 |
| G&A Expenses | $3 | $2 | $2 | $1 |
| SG&A Expenses | $3 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $9 | $8 | $5 |
| Operating Income | -$16 | -$9 | -$8 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$16 | -$9 | -$8 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$9 | -$8 | -$5 |
| % Margin | – | – | – | – |
| EPS | -1.21 | -0.69 | -0.61 | -0.35 |
| % Growth | -75.4% | -13.1% | -74.3% | – |
| EPS Diluted | -1.21 | -0.69 | -0.61 | -0.35 |
| Weighted Avg Shares Out | 13 | 13 | 13 | 13 |
| Weighted Avg Shares Out Dil | 13 | 13 | 13 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$9 | -$8 | -$5 |
| % Margin | – | – | – | – |